Étiquette : thérapeutiques psychédeliques

Psycholytic and Psychedelic Therapy Research 1931-1995 : A Complete International Bibliography, Torsten Passie, 1997

Psycholytic and Psychedelic Therapy Research 1931-1995 : A Complete International Bibliography Torsten Passie Laurentius Publishers, Hannover, Germany, 1997 Kleine bibliographische Reihe, vol. 3. (Ed. Raimund Dehmlow), ISSN 0941-6617 ISBN 3-931614-83-2 (cloth), ISBN 3-931614-84-0 (pbk)   Preface I. Introduction     9 II. Organization of the Bibliography     21 III. Bibliography 1. General Approach and Basic Research    23 2. Psycholytic Therapy     42 3. Psychedelic Therapy    70 IV. Major Scientific Conferences on the Subject    88 V. Major Bibliographic Sources   89 Author Index    90 Subject Index    95 About the Authors     102  

Lire la suite

Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution, M. V. Uthaug et al., 2018

Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution M. V. Uthaug, K. van Oorsouw, K. P. C. Kuypers, M. van Boxtel, N. J. Broers, N. L. Mason, S. W. Toennes, J. Riba, J. G. Ramaekers Psychopharmacology, 2018 https://doi.org/10.1007/s00213-018-4988-3   Abstract Rationale : Ayahuasca is a psychotropic plant tea from South America used for religious purposes by indigenous people of the Amazon. Increasing evidence indicates that ayahuasca may have therapeutic potential in the treatment of mental health disorders and can enhance mindfulness-related capacities. Most research so far has focused on acute and sub-acute effects of ayahuasca on [...]

Lire la suite

Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users, Genís Ona et al., 2019

Ayahuasca and Public Health : Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users Genís Ona, Maja Kohek, Tomàs Massaguer, Alfred Gomariz, Daniel F. Jiménez, Rafael G. Dos Santos, Jaime E. C. Hallak, Miguel Ángel Alcázar- Córcoles & José Carlos Bouso Journal of Psychoactive Drugs, 2019, DOI: 10.1080/02791072.2019.1567961   ABSTRACT Assessing the health status of ayahuasca users has been challenging due to the limitations involved in randomized clinical trials and psychometric approaches. The main objective of this study is the implementation of an approach based on public health indicators. We developed a self-administered questionnaire that was administered to long-term [...]

Lire la suite

Implications for psychedelic-assisted psychotherapy : functional magnetic resonnance imaging study with psilocybin, Robin L. Carhart-Harris et al., 2012

Implications for psychedelic-assisted psychotherapy : a functional magnetic resonance imaging study with psilocybin R. L. Carhart-Harris, R. Leech, T. M. Williams, D. Erritzoe, N. Abbasi, T. Bargiotas, P. Hobden, D. J. Sharp, J. Evans, A. Feilding, R. G. Wise and D. J. Nutt British Journal of Psychiatry, 2012, 200, 238-244. Doi : 10.1192/bjp.bp.111.103309   Background Psilocybin is a classic psychedelic drug that has a history of use in psychotherapy. One of the rationales for its use was that it aids emotional insight by lowering psychological defences. Aims To test the hypothesis that psilocybin facilitates access to personal memories and emotions by comparing subjective and neural responses to positive [...]

Lire la suite

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybine, Robin L. Carhart-Harris et al., 2012

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybine Robin L. Carhart-Harris, David Erritzoe, Tim Williams, James M. Stone, Laurence J. Reed, Alessandro Colasanti, Robin J. Tyacke, Robert Leech, Andrea L. Malizia, Kevin Murphy, Peter Hobden, John Evans, Amanda Feilding, Richard G. Wise, and David J. Nutt PNAS, Proceedings of the National Academy of Sciences of the USA, 2012, 109, (6), 2138-2143. doi:10.1073/pnas.1119598109 www.pnas.org/lookup/suppl/doi:10.1073/pnas.1119598109/-/DCSupplemental.   Abstract Psychedelic drugs have a long history of use in healing ceremonies, but despite renewed interest in their therapeutic potential, we continue to know very little about howthey work in the brain. Here we used psilocybin, a classic [...]

Lire la suite

Prohibited or regulated ? LSD psychotherapy and the United States Food and Drug Administration, Matthew Oram, 2016

Prohibited or regulated ? LSD psychotherapy and the United States Food and Drug Administration Matthew Oram History of Psychiatry, 2016, 27, (3), 290-306. Doi : 10.1177/0957154X16648822 Abstract Over the 1950s and early 1960s, the use of the hallucinogenic drug lysergic acid diethylamide (LSD) to facilitate psychotherapy was a promising field of psychiatric research in the USA. However, during the 1960s, research began to decline, before coming to a complete halt in the mid-1970s. This has commonly been explained through the increase in prohibitive federal regulations during the 1960s that aimed to curb the growing recreational use of the drug. However, closely examining the Food and Drug [...]

Lire la suite

From experimental psychosis to resolving traumatic pasts – Psychedelic Research in Communist Czechoslovakia, 1954‑1974, Sarah Marks, 2015

From experimental psychosis to resolving traumatic pasts - Psychedelic Research in Communist Czechoslovakia, 1954‑1974 De la psychose expérimentale à la guérison des traumatismes du passé : la recherche psychédélique en Tchécoslovaquie communiste, 1954‑1974 Sarah Marks Cahiers du monde russe, 2015, 56, 1, 53-75. DOI: 10.4000/monderusse.8165   The mid‑twentieth century saw an abundance of new theories of human behaviour and mental disorder, many of which were inspired by new developments in broader scientific fields, from cybernetics and genetics, to pharmaceuticals and new technologies of psychological testing1. There is a developing historical literature on the development of psychiatry in Western Europe and North America, yet we know little [...]

Lire la suite

Flashback : Psychiatric Experimentation With LSD in Historical Perspective, Erika Dyck, 2005

Flashback : Psychiatric Experimentation With LSD in Historical Perspective Erika Dyck Canadian Journal of Psychiatry, 2005, Vol 50, No 7, 381-388. Doi : 10.1177/070674370505000703   In the popular mind, d-lysergic acid diethylamide (LSD) research in psychiatry has long been associated with the CIA-funded experiments conducted by Ewen Cameron at the Allen Memorial Institute in Montreal, Quebec. Despite this reputation, a host of medical researchers in the post–World War II era explored LSD for its potential therapeutic value. Some of the most widespread trials in the Western world occurred in Saskatchewan, under the direction of psychiatrists Humphry Osmond (in Weyburn) and Abram Hoffer (in Saskatoon). These [...]

Lire la suite

Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study, Alicia L. Danforth, Charles S. Grob et al., 2018

Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults : a randomized, double-blind, placebo-controlled pilot study Alicia L. Danforth, Charles S. Grob, Christopher Struble, Allison A. Feduccia, Nick Walker, Lisa Jerome, Berra Yazar-Klosinski & Amy Emerson Psychopharmacology, 2018, https://doi.org/10.1007/s00213-018-5010-9   Abstract Rationale : Standard therapeutic approaches to reduce social anxiety in autistic adults have limited effectiveness. Since 3,4- methylenedioxymethamphetamine (MDMA)-assisted psychotherapy shows promise as a treatment for other anxiety disorders, a blinded, placebo-controlled pilot study was conducted. Objectives : To explore feasibility and safety ofMDMA-assisted psychotherapy for reduction of social fear and avoidance that are common in the autistic population. Methods : Autistic adults with marked to [...]

Lire la suite

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer, Charles S. Grob et al., 2010

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Charles S. Grob,  Alicia L. Danforth,  Gurpreet S. Chopra,  Marycie Hagerty, Charles R. McKay, Adam L. Halberstadt,  George R. Greer Archive of  General Psychiatry, 2010, 68, (1), 71–78 doi: 10.1001/archgenpsychiatry.2010.116   Context : Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. Objective : To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and [...]

Lire la suite